USP10-mediated deubiquitination and activation of <i>KRAS</i> mutants promotes colorectal cancer <i>via</i> a novel USP10/KRAS positive feedback circuit. [PDF]
Acta Pharm Sin BYuan T +14 more
europepmc +1 more source
Non-invasive identification of KRAS mutation in rectal cancer using hybrid intravoxel incoherent motion and diffusion kurtosis model. [PDF]
World J Surg OncolYuan J +9 more
europepmc +1 more source
Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation. [PDF]
Case Rep Oncol MedAntonios B, Abioye O, Park SJ, Finley G.
europepmc +1 more source
Case Report: Pulmonary enteric adenocarcinoma harboring KRAS/TP53/APC mutations with contralateral lung metastasis: diagnostic challenges and molecular insights. [PDF]
Front OncolMao M, Hu M, Tao Q, Zuo Z, Liu B.
europepmc +1 more source
Characteristics of <i>KRAS</i> WT pancreatic adenocarcinomas: results of a large French multicentric cohort. [PDF]
Ther Adv Med OncolTrystram N +14 more
europepmc +1 more source
KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
Tubita A +12 more
openalex +1 more source
Related searches:
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites.
Bob T Li, Eileen M O'reilly
exaly +3 more sources
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other ...
Daniel A, Erlanson, Kevin R, Webster
openaire +2 more sources